Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in High Risk Renal Cell Carcinoma
NCT01070186Phase 2Withdrawn
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Oct 2010
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of sunitinib in renal cell carcinoma (RCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Planned start Oct 2010; status: withdrawn.
02
Drugs
sunitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01070186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01070186.